Tumor immune evasion arises through loss of TNF sensitivity
The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
Whole-genome CRISPR screens identify resistance to TNF-mediated killing by T and NK cells as a tumor immune evasion mechanism.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“IFN γ and TNF α are key effector cytokines that contribute to anti-tumour immune responses 9,11,27-30 , and genes associated with IFN and TNF signaling pathways contribute to immune evasion 4,9,29 .”
From Targeting TBK1 to overcome resistance to cancer immunotherapy (2023) · cites this paper as [29]
In the citing paper
“Single-guide RNAs targeting genes involved in IFN γ sensing (Ifngr1, Ifgnr2, Jak1, Jak2, and Stat1) were enriched in control and Tbk1-null cells (Fig. 5d, Extended Data Fig. 10a), consistent with previous in vivo and in vitro screens 4,29 .”
From Targeting TBK1 to overcome resistance to cancer immunotherapy (2023) · cites this paper as [29]
Citations
Cites
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9
Doench, J. G., Fusi, N., Sullender, M., Hegde, M., Vaimberg, E. W., Donovan, K. F., Smith, I., Tothova, Z., Wilen, C., Orchard, R., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3437 · Cited by 4,637 · cited 1×
“The mouse cell lines MC38-Cas9, MC38OvaCas9, and B16Ova-Cas9 cells were transduced with the Brie genome-wide sgRNA library (40), and the human cell line MDA-MB-231 was transduced with the Brunello genome-wide sgRNA library.”
MethodMutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D. Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604958 · Cited by 3,237 · cited 3×
“Gene mutations that reduce the efficacy of immunotherapy have recently been identified, including mutations in Janus kinases (JAK) providing resistance to anti–PD-1 therapy (9).”
BackgroundClonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
McGranahan, N., Furness, A. J. S., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S. K., Jamal-Hanjani, M., Wilson, G. A., Birkbak, N. J., Hiley, C. T., et al. (2016) · Science · doi:10.1126/science.aaf1490 · Cited by 3,065
Li, W., Xu, H., Xiao, T., Cong, L., Love, M. I., Zhang, F., Irizarry, R. A., Liu, J. S., Brown, M., & Liu, X. S. (2014) · Genome Biology · doi:10.1186/s13059-014-0554-4 · Cited by 2,684
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
Shin, D. S., Zaretsky, J. M., Escuin-Ordinas, H., Garcia-Diaz, A., Hu-Lieskovan, S., Kalbasi, A., Grasso, C. S., Hugo, W., Sandoval, S., Torrejon, D. Y., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1223 · Cited by 1,337
Perforin and granzymes: function, dysfunction and human pathology
Voskoboinik, I., Whisstock, J. C., & Trapani, J. A. (2015) · Nature Reviews Immunology · doi:10.1038/nri3839 · Cited by 1,327
Self-citationGenome-scale CRISPR-Cas9 Knockout and Transcriptional Activation Screening
Joung, J., Konermann, S., Gootenberg, J. S., Abudayyeh, O. O., Platt, R. J., Brigham, M. D., Sanjana, N. E., & Zhang, F. (2017) · Nature Protocols · doi:10.1038/nprot.2017.016 · Cited by 1,243 · cited 1×
“Genomic DNA extraction was subsequently performed using the DNeasy Blood & Tissue Kit (Qiagen), and libraries were prepared as described previously (41).”
MethodIn vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target
Manguso, R. T., Pope, H. W., Zimmer, M. D., Brown, F. D., Yates, K. B., Miller, B. C., Collins, N. B., Bi, K., LaFleur, M. W., Juneja, V. R., et al. (2017) · Nature · doi:10.1038/nature23270 · Cited by 1,147
Cited by
Items 101–200 of 405
Zhang, Y., Zhao, M., Gao, H., Yu, G., Zhao, Y., Yao, F., & Yang, W. (2022) · Nature Metabolism · doi:10.1038/s42255-022-00543-7 · Cited by 53
Exhausted T cells hijacking the cancer-immunity cycle: Assets and liabilities
Brunell, A. E., Lahesmaa, R., Autio, A. K., & Thotakura, A. K. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1151632 · Cited by 52
SLFN11 can sensitize tumor cells towards IFN-γ-mediated T cell killing
Mezzadra, R., de Bruijn, M. J. W., Jae, L. T., Gomez, R., Duursma, A. M., Scheeren, F. A., Brummelkamp, T. R., & Schumacher, T. N. (2019) · PLoS ONE · doi:10.1371/journal.pone.0212053 · Cited by 51
Ferroptosis‐Enhanced Cancer Immunity by a Ferrocene‐Appended Iridium(III) Diphosphine Complex
Wang, W., Ling, Y., Zhong, Y., Li, Z., Tan, C., & Mao, Z. (2021) · Angewandte Chemie · doi:10.1002/ange.202115247 · Cited by 51
Lawal, B., Tseng, S., Olugbodi, J. O., Iamsaard, S., Ilesanmi, O. B., Mahmoud, M. H., Ahmed, S. S. E.-D., Batiha, G. E., & Wu, A. T. H. (2021) · Cancers · doi:10.3390/cancers13164124 · Cited by 51
Mechanisms of Immunosuppressive Tumor Evasion: Focus on Acute Lymphoblastic Leukemia
Jiménez‐Morales, S., Aranda-Uribe, I. S., Pérez-Amado, C. J., Ramírez‐Bello, J., & Hidalgo‐Miranda, A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.737340 · Cited by 50
Cytokine-armed pyroptosis induces antitumor immunity against diverse types of tumors
Orehek, S., Ramuta, T. Ž., Lainšček, D., Malenšek, Š., Šala, M., Benčina, M., Jerala, R., & Hafner‐Bratkovič, I. (2024) · Nature Communications · doi:10.1038/s41467-024-55083-3 · Cited by 49
Management of rheumatic complications of ICI therapy: a rheumatology viewpoint
Leipe, J., & Mariette, X. (2019) · Rheumatology · doi:10.1093/rheumatology/kez360 · Cited by 48
CRISPR screen in mechanism and target discovery for cancer immunotherapy
Liu, D., Zhao, X., Tang, A., Xu, X., Liu, S., Zha, L., Ma, W., Zheng, J., & Shi, M. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188378 · Cited by 48
25 years of research put RIPK1 in the clinic
Liu, L., & Lalaoui, N. (2020) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2020.08.007 · Cited by 48
Self-citationWolf, N. K., Blaj, C., Picton, L. K., Snyder, G., Zhang, L., Nicolai, C. J., Ndubaku, C. O., McWhirter, S. M., García, K. C., & Raulet, D. H. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2200568119 · Cited by 48
Perturbomics: CRISPR–Cas screening-based functional genomics approach for drug target discovery
Park, B.-S., Lee, M., Kim, J. Y., & Kim, T. (2025) · Experimental & Molecular Medicine · doi:10.1038/s12276-025-01487-0 · Cited by 47
Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity Threshold
Vredevoogd, D. W., Kuilman, T., Ligtenberg, M. A., Boshuizen, J., Stecker, K. E., de Bruijn, B., Krijgsman, O., Huang, X., Kenski, J. C. N., Lacroix, R., et al. (2020) · Cell · doi:10.1016/j.cell.2020.01.005 · Cited by 47
RNA N4‐acetylcytidine modification and its role in health and diseases
Wang, Q., Yuan, Y., Zhou, Q., Jia, Y., Liu, J. L., Xiao, G., Li, C., & Jiang, X. (2025) · MedComm · doi:10.1002/mco2.70015 · Cited by 45
Modulation of CD4 T Cell Response According to Tumor Cytokine Microenvironment
Accogli, T., Bruchard, M., & Végran, F. (2021) · Cancers · doi:10.3390/cancers13030373 · Cited by 45
Visram, A., Dasari, S., Anderson, E., Kumar, S. K., & Kourelis, T. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00440-4 · Cited by 45
Revving the CAR – Combination strategies to enhance CAR T cell effectiveness
Bansal, R., & Reshef, R. (2020) · Blood Reviews · doi:10.1016/j.blre.2020.100695 · Cited by 44
Mesenchymal ovarian cancer cells promote CD8+ T cell exhaustion through the LGALS3-LAG3 axis
Yakubovich, E., Cook, D. P., Rodriguez, G. M., & Vanderhyden, B. C. (2023) · npj Systems Biology and Applications · doi:10.1038/s41540-023-00322-4 · Cited by 43
Sukocheva, O. A., Неганова, М. Е., Aleksandrova, Y. R., Burcher, J. T., Chugunova, E., Fan, R., Tse, E., Sethi, G., Bishayee, A., & Liu, J. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01626-6 · Cited by 43
Tumor Immune Evasion Induced by Dysregulation of Erythroid Progenitor Cells Development
Grzywa, T. M., Justyniarska, M., Nowis, D., & Gołąb, J. (2021) · Cancers · doi:10.3390/cancers13040870 · Cited by 43
Blockade of HVEM for Prostate Cancer Immunotherapy in Humanized Mice
Aubert, N., Brunel, S., Olive, D., & Marodon, G. (2021) · Cancers · doi:10.3390/cancers13123009 · Cited by 43
Kim, I., Diamond, M. S., Yuan, S., Kemp, S. B., Kahn, B., Li, Q., Lin, J. H., Li, J., Norgard, R. J., Thomas, S. K., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46048-7 · Cited by 43
Mechanistic insights into resistance mechanisms to T cell engagers
Cao, L., Leclercq-Cohen, G., Klein, C., Sorrentino, A., & Bacac, M. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1583044 · Cited by 42
Shen, Y., Eng, J. S., Fajardo, F., Liang, L., Li, C., Collins, P. J., Tedesco, D., & Nolan-Stevaux, O. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004348 · Cited by 41
Emerging roles of TBK1 in cancer immunobiology
Miranda, A., Shirley, C. A., & Jenkins, R. W. (2024) · Trends in cancer · doi:10.1016/j.trecan.2024.02.007 · Cited by 39
Epigenetic modification of CSDE1 locus dictates immune recognition of nascent tumorigenic cells
Lv, J., Zhou, Y., Zhou, N., Wang, Z., Chen, J., Chen, H., Wang, D., Zhou, L., Wei, K., Zhang, H., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abq6024 · Cited by 39
LAG‐3 : recent developments in combinational therapies in cancer
Chavanton, A., Mialhe, F., Abrey, J., Garcia, A. B., & Garrido, C. (2024) · Cancer Science · doi:10.1111/cas.16205 · Cited by 38
Yu, T., Nie, W., Hong, Z., He, Y., Chen, J., Mi, X., Yang, S., Li, X., Wang, B., Lin, Y., et al. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202100715 · Cited by 38
Discovery of Targets for Immune–Metabolic Antitumor Drugs Identifies Estrogen-Related Receptor Alpha
Sahu, A. D., Wang, X., Munson, P. B., Klomp, J. P. G., Wang, X., Gu, S. S., Qian, G., Nicol, P., Zeng, Z., Wang, C., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0244 · Cited by 37
Steven, N. M., & Fisher, B. A. (2019) · Rheumatology · doi:10.1093/rheumatology/kez536 · Cited by 36
Tumor immunology CRISPR screening: present, past, and future
Dong, M. B., Tang, K., Zhou, X., Zhou, J. J., & Chen, S. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.11.009 · Cited by 36
Guo, Z., Zhou, C., Zhou, L., Wang, Z., Zhu, X., & Mu, X. (2021) · Cellular Immunology · doi:10.1016/j.cellimm.2021.104469 · Cited by 35
Tang, L., Zhang, H., Zhou, F., Wei, Q., Du, M., Wu, J., Li, C., Luo, W., Zhou, J., Wang, X., et al. (2024) · 癌症:英文版 · doi:10.1002/cac2.12525 · Cited by 34
Hantavirus Inhibits TRAIL-Mediated Killing of Infected Cells by Downregulating Death Receptor 5
Solà-Riera, C., Gupta, S., Maleki, K. T., González-Rodríguez, P., Saidi, D., Zimmer, C. L., Vangeti, S., Rivino, L., Leo, Y., Lye, D. C., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.07.066 · Cited by 34
Paschen, A., Melero, I., & Ribas, A. (2021) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-070220-111016 · Cited by 36
Worel, N., Grabmeier‐Pfistershammer, K., Kratzer, B., Schlager, M., Tanzmann, A., Rottal, A., Körmöczi, U., Porpaczy, E. A., Staber, P. B., Skrabs, C., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1004703 · Cited by 34
Walsh, M. J., Ali, L. R., Lenehan, P. J., Kureshi, C. T. S., Kureshi, R., Dougan, M. L., Knipe, D. M., & Dougan, S. K. (2023) · Immunotherapy Advances · doi:10.1093/immadv/ltad011 · Cited by 33
Gupta, R., Chauhan, A., Kaur, T., Kuanr, B. K., & Sharma, D. (2024) · ACS Nano · doi:10.1021/acsnano.4c03887 · Cited by 33
RIPK1‐mediated immunogenic cell death promotes anti‐tumour immunity against soft‐tissue sarcoma
Smith, H. G., Jamal, K., Dayal, J. H. S., Tenev, T., Kyula, J., Guppy, N., Gazińska, P., Roulstone, V., Liccardi, G., Davies, E., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.201910979 · Cited by 33
HOIP limits anti-tumor immunity by protecting against combined TNF and IFN-gamma-induced apoptosis
Freeman, A. J., Vervoort, S. J., Michie, J., Ramsbottom, K. M., Silke, J., Kearney, C. J., & Oliaro, J. (2021) · EMBO Reports · doi:10.15252/embr.202153391 · Cited by 33
Self-citationAntimetastatic defense by CD8+ T cells
de Lara, P. T., Castañón, H., Sterpi, M., & van den Broek, M. F. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.10.006 · Cited by 33
NKG7 Enhances CD8+ T Cell Synapse Efficiency to Limit Inflammation
Lelliott, E. J., Ramsbottom, K. M., Dowling, M. R., Shembrey, C., Noori, T., Kearney, C. J., Michie, J., Parish, I. A., Jordan, M. A., Baxter, A. G., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.931630 · Cited by 32
Self-citationFacing the future: challenges and opportunities in adoptive T cell therapy in cancer
Magalhaes, I., Carvalho‐Queiroz, C., Hartana, C. A., Kaiser, A. M., Lukic, A., Mints, M., Nilsson, O., Grönlund, H., Mattsson, J., & Berglund, S. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1608179 · Cited by 32
Clonal tracing reveals diverse patterns of response to immune checkpoint blockade
Gu, S. S., Wang, X., Hu, X. S., Jiang, P., Li, Z., Traugh, N. C., Bu, X., Tang, Q., Wang, C., Zeng, Z., et al. (2020) · Genome biology · doi:10.1186/s13059-020-02166-1 · Cited by 32
Integrated clinical and genomic evaluation of guadecitabine (SGI-110) in peripheral T-cell lymphoma
Wong, J., Gruber, E., Maher, B. M., Waltham, M. C., Sabouri-Thompson, Z., Jong, I., Luong, Q., Levy, S. M., Kumar, B., Brasacchio, D., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01571-8 · Cited by 32
Self-citationWang, Y., Qian, J., Xu, W., Wang, J., Li, Z., Tan, G., & Suo, A. (2022) · Advanced Functional Materials · doi:10.1002/adfm.202208486 · Cited by 32
PRMT1 acts as a suppressor of MHC-I and anti-tumor immunity
Djajawi, T. M., Pijpers, L., Srivaths, A., Chisanga, D., Chan, K. F., Hogg, S. J., Neil, L., Rivera, S., Bartoniček, N., Ellis, S. L., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.113831 · Cited by 32
Self-citationGrainyhead-like-2 confers NK-sensitivity through interactions with epigenetic modifiers
MacFawn, I., Wilson, H. E., Selth, L. A., Leighton, I. A., Serebriiskii, I. G., Bleackley, R. C., Elzamzamy, O. M., Farris, J. C., Pifer, P. M., Richer, J. K., et al. (2018) · Molecular Immunology · doi:10.1016/j.molimm.2018.11.006 · Cited by 31
Bridging Radiotherapy to Immunotherapy: The IFN–JAK–STAT Axis
Shi, L. Z., & Bonner, J. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212295 · Cited by 30
Shen, H., Huang, F., Zhang, X., Ojo, O. A., Li, Y., Trummell, H. Q., Anderson, J. C., Fiveash, J. B., Bredel, M., Yang, E. S.-H., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32754-7 · Cited by 30
Chun, N. H., Ang, R. L., Chan, M., Fairchild, R. L., Baldwin, W. M., Horwitz, J. K., Gelles, J. D., Chipuk, J. E., Kelliher, M. A., Pavlov, V. I., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.148643 · Cited by 31
Howard, E. D., Hurrell, B. P., Helou, D. G., Quach, C., Painter, J. D., Shafiei-Jahani, P., Fung, M., Gill, P. S., Soroosh, P., Sharpe, A. H., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.733136 · Cited by 29
Ho, W. J., Yarchoan, M. M., Charmsaz, S., Munday, R. M., Danilova, L., Sztein, M. B., Fertig, E. J., & Jaffee, E. M. (2019) · JCI Insight · doi:10.1172/jci.insight.132286 · Cited by 29
Deng, X., Shen, Y., Yi, M., Zhang, C. H., Zhao, B., Zhong, G., WeiyangLou, Xue, D., Leng, Q., Ding, J., et al. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28768 · Cited by 28
Bypassing anti-PD-(L)1 therapy: Mechanisms and management strategies
Mortezaee, K., Majidpoor, J., Najafi, S., & Tasa, D. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.114150 · Cited by 27
SOX10 Loss Sensitizes Melanoma Cells to Cytokine-Mediated Inflammatory Cell Death
Rosenbaum, S. R., Caksa, S., Stefanski, C. D., Trachtenberg, I. V., Wilson, H. P., Wilski, N. A., Ott, C. A., Purwin, T. J., Haj, J. I., Pomante, D., et al. (2023) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-23-0290 · Cited by 27
Tatsuguchi, T., Uruno, T., Sugiura, Y., Sakata, D., Izumi, Y., Sakurai, T., Hattori, Y., Oki, E., Kubota, N., Nishimoto, K., et al. (2022) · International Immunology · doi:10.1093/intimm/dxac002 · Cited by 27
Oncolytic Virotherapy: The Cancer Cell Side
Ehrlich, M., & Bacharach, E. (2021) · Cancers · doi:10.3390/cancers13050939 · Cited by 26
Liu, J., Wang, P., Huang, B., Cheng, Q., Duan, Y., Chen, L., Ma, T., Zhu, C., Li, D., Fan, W., et al. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.121969 · Cited by 26
Chauhan, A., Anjaly, K., Saini, A., Kumar, R., Kuanr, B. K., & Sharma, D. (2023) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.3c01702 · Cited by 26
Gu, Y., Zhang, Z., Camps, M. G. M., OSSENDORP, F. A., Wijdeven, R. H. M., & ten Dijke, P. (2023) · Science Advances · doi:10.1126/sciadv.adf9915 · Cited by 26
Hashemi, M., Khosroshahi, E. M., Tanha, M., Khoushab, S., Bizhanpour, A., Azizi, F., Mohammadzadeh, M., Matinahmadi, A., Koohpar, Z. K., Asadi, S., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e37376 · Cited by 26
Bystander Effects of Nitric Oxide in Cellular Models of Anti-Tumor Photodynamic Therapy
Bazak, J., Korytowski, W., & Girotti, A. W. (2019) · Cancers · doi:10.3390/cancers11111674 · Cited by 26
Wu, G., Li, D., Liang, W. P., Sun, W., Xie, X., Tong, Y., Shan, B., Zhang, M., Lu, X., Yuan, J., et al. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05206-9 · Cited by 25
When Cancer Cells Become the Enablers of an Antitumor Immune Response
Ribas, A., Haining, W. N., & Schumacher, T. N. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0706 · Cited by 25
Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell–Secreted Cytokines
Ito, Y., Pan, D., Zhang, W., Zhang, X., Juan, T. Y., Pyrdol, J. W., Kyrysyuk, O., Doench, J. G., Liu, X. S., & Wucherpfennig, K. W. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1125 · Cited by 25
Enhanced cellular therapy: revolutionizing adoptive cellular therapy
Xu, M., Zeng, N., Liu, C., Sun, J., An, Y., Zhang, S.-H., Xu, J., Zhong, X., Ma, S., He, H., et al. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00506-6 · Cited by 25
A Highlight of the Mechanisms of Immune Checkpoint Blocker Resistance
Huang, Q., Lei, Y., Li, X., Guo, F., & Liu, M. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.580140 · Cited by 25
BET Inhibition Enhances TNF-Mediated Antitumor Immunity
Wellinger, L. C., Hogg, S. J., Newman, D. M., Friess, T., Geiss, D., Michie, J., Ramsbottom, K. M., Bacac, M., Fauti, T., Marbach, D., et al. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0224 · Cited by 24
Self-citationSorrentino, A., Menevse, A. N., Michels, T., Volpin, V., Durst, F. C., Sax, J., Xydia, M., Hussein, A., Stamova, S., Spoerl, S., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004258 · Cited by 24
Jou, E. (2023) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2023.00146 · Cited by 23
Zhuang, X., Woods, J., Ji, Y., Scheich, S., Mo, F., Rajagopalan, S., Coulibaly, Z. A., Voß, M., Urlaub, H., Staudt, L. M., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114105 · Cited by 23
How Can We Engineer CAR T Cells to Overcome Resistance?
Glover, M., Avraamides, S., & Maher, J. F. (2021) · Biologics · doi:10.2147/btt.s252568 · Cited by 23
Mechanisms of resistance to T cell‐based immunotherapy in head and neck cancer
Lee, M. Y., & Allen, C. T. (2020) · Head & Neck · doi:10.1002/hed.26158 · Cited by 24
Roles of cytotoxic and helper innate lymphoid cells in cancer
Guillerey, C. (2018) · Mammalian Genome · doi:10.1007/s00335-018-9781-4 · Cited by 22
Li, M., Sun, J., & Shi, G. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1220376 · Cited by 21
Fn14 and TNFR2 as regulators of cytotoxic TNFR1 signaling
Siegmund, D., Zaitseva, O., & Wajant, H. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1267837 · Cited by 21
Multimodal stimulation screens reveal unique and shared genes limiting T cell fitness
Lin, C., Levy, P. L., Alflen, A., Apriamashvili, G., Ligtenberg, M. A., Vredevoogd, D. W., Bleijerveld, O. B., Alkan, F., Malka, Y., Hoekman, L., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.02.016 · Cited by 21
Iridium(III)-Based PD-L1 Agonist Regulates p62 and ATF3 for Enhanced Cancer Immunotherapy
Deng, D., Wang, M., Su, Y. R., Fang, H., Chen, Y., & Su, Z. G. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00404 · Cited by 21
He, Y., Yang, D., Lin, X., Zhang, J., Cheng, R., Cao, L., Yang, L., Zhang, M., Shi, X., Jin, X., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1412693 · Cited by 20
Wu, S., Liu, H., Li, S., Sun, H., He, X., Huang, Y., & Long, H. (2021) · Marine Drugs · doi:10.3390/md19040217 · Cited by 20
Choucair, K., Radford, M., Bansal, A. K., Park, R., & Saeed, A. (2021) · International Journal of Oncology · doi:10.3892/ijo.2021.5254 · Cited by 20
Cancer vaccines: Discovery, development, and challenges for clinical translation
Zhang, Z., Yao, S., Wang, Y., Luo, K., Amiji, M. M., & Anderson, K. C. (2025) · Biomaterials · doi:10.1016/j.biomaterials.2025.123615 · Cited by 19
The role of cytokines in cytokine release syndrome (CRS) after CAR T cell therapy
Gabriel, K., Heinzerling, L., von Baumgarten, L., Subklewe, M. S., & Kobold, S. (2026) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2026.120115 · Cited by 19
Qian, L., Xie, L. Y., Zhu, Y., Huang, C., & Meng, Z. (2023) · Liver International · doi:10.1111/liv.15817 · Cited by 19
Exploring the potential of Toxoplasma gondii in drug development and as a delivery system
Yoon, C., Ham, Y. S., Gil, W. J., & Yang, C. (2024) · Experimental & Molecular Medicine · doi:10.1038/s12276-024-01165-7 · Cited by 19
Liang, R., Li, P., Yang, N., Xiao, X., Gong, J., Zhang, X., Bai, Y., Chen, Y., Xie, Z., & Liao, Q. (2024) · Drug Design Development and Therapy · doi:10.2147/dddt.s457338 · Cited by 19
Fenaux, J., Fang, X., Huang, Y.-M., Melero, C., Bonnans, C., Lowe, E. L., Palumbo, T., Lay, C., Yi, Z., Zhou, A., et al. (2023) · OncoImmunology · doi:10.1080/2162402x.2023.2217737 · Cited by 19
Tian, Y., Holdship, P., To, T. Q., Ratcliffe, P. J., & Keeley, T. P. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.105156 · Cited by 19
Long, Y., Chen, R., Yu, X., Tong, Y., Peng, X., Li, F., Hu, C., Sun, J., & Gong, L. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0439 · Cited by 18
Lafont, É. (2020) · Cancers · doi:10.3390/cancers12051113 · Cited by 18
Intracellular zinc protects tumours from T cell-mediated cytotoxicity
Lelliott, E. J., Naddaf, J., Ganio, K., Michie, J., Wang, S., Liu, L., Silke, N., Ahn, A., Ramsbottom, K. M., Brennan, A. J., et al. (2024) · Cell Death and Differentiation · doi:10.1038/s41418-024-01369-4 · Cited by 17
Self-citationLee, S. C.-E. S., Pyo, A. H. A., Mohammadi, H., Zhang, J., Dvorkin‐Gheva, A., Malbeteau, L., Chung, S., Khan, S., Ciudad, M. T., Rondeau, V., et al. (2024) · Science Advances · doi:10.1126/sciadv.adq0355 · Cited by 17
The head and neck cancer genome in the era of immunotherapy
Wijetunga, N. A., Yu, Y., Morris, L. G. T., Lee, N. Y., & Riaz, N. (2020) · Oral Oncology · doi:10.1016/j.oraloncology.2020.105040 · Cited by 18
Tumor mechanisms of resistance to immune attack
Zahavi, D. J., & Weiner, L. M. (2019) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2019.03.009 · Cited by 17
CRISPR-Cas, a robust gene-editing technology in the era of modern cancer immunotherapy
Miri, S. M., Tafsiri, E., Cho, W. C. S., & Ghaemi, A. (2020) · Cancer Cell International · doi:10.1186/s12935-020-01546-8 · Cited by 17
Cai, Y., Li, X., Zhu, S., Wu, H., Nie, J., & Huang, F. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.116125 · Cited by 16
Yang, C., Jiang, Y., Zhang, K., Zhu, X., Li, J., Yu, H., Chen, J., Gu, X., Gan, Z., & Yu, Q. (2024) · Small · doi:10.1002/smll.202308456 · Cited by 16
Functional profiling of murine glioma models highlights targetable immune evasion phenotypes
Mikolajewicz, N., Tatari, N., Wei, J., Savage, N. J., Farias, A. G., Dimitrov, V., Chen, D. Y., Zador, Z. E., Dasgupta, K., Aguilera-Uribe, M., et al. (2024) · Acta Neuropathologica · doi:10.1007/s00401-024-02831-w · Cited by 16
Self-citationJiramongkol, Y., Patel, K., Johansen‐Leete, J., Maxwell, J. W. C., Chang, Y., Du, J. J., Passioura, T., Cook, K. M., Payne, R. J., & White, M. D. (2025) · Nature Communications · doi:10.1038/s41467-025-59960-3 · Cited by 16
Metadata
- Authors
- Kearney, C. J., Vervoort, S. J., Hogg, S. J., Ramsbottom, K. M., Freeman, A. J., Lalaoui, N., Pijpers, L., Michie, J., Brown, K. K., Knight, D. A., Sutton, V., Beavis, P. A., Voskoboinik, I., Darcy, P. K., Silke, J., Trapani, J. A., Johnstone, R. W., & Oliaro, J.
- Affiliations
- The University of Melbourne (AU)
- Peter MacCallum Cancer Centre (AU)
- Walter and Eliza Hall Institute of Medical Research (AU)
- Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria 3052, Australia.
- Corresponding author
- Kearney, Conor J.
- Vervoort, Stephin J.
- Johnstone, Ricky W.
- Oliaro, Jane
- ORCID
- Venue
- Science Immunology
- Published
- 2018-05-04
- Volume
- 3
- Issue
- 23
- ISSN
- 2470-9468 (ISSN-L)
- OpenAlex
- W2804568941
- Cited by
- 381
- References
- 46
- Citations by year
- 2026: 20 · 2025: 59 · 2024: 61 · 2023: 59 · 2022: 55 · 2021: 54 · 2020: 38 · 2019: 26 · 2018: 7
- FWCI
- 11.72
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science Immunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Victorian Cancer Agency
- National Health and Medical Research Council
- Cancer Council Victoria
- National Breast Cancer Foundation (ECF-17-005)
- Netherlands Organization for Scientific Research
- Peter MacCallum Cancer Foundation
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Keywords
- tumor immune evasion, TNF signaling, T cell-mediated killing, NK cell-mediated killing, interferon signaling, antigen presentation, immune surveillance, tumor immunology
- MeSH terms
- Animals, Interferon-gamma, Killer Cells, Natural, Tumor Necrosis Factor-alpha, Antigen Presentation, CD8-Positive T-Lymphocytes, Tumor Escape, Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.